TP53
TP53 is a tumor suppressor gene involved in cell cycle control and apoptosis. Mutations are common across cancers and inform prognosis and therapy strategies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where TP53 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
B-cell Chronic Lymphocytic Leukemia (CLL) Heme · Leukemia |
|
Approvals defined at the solid tumor level where TP53 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report TP53 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports TP53 as part of its biomarker panel.